Valuation
- Market cap
- 66,789,000
- Revenue TTM
- $48,470,000
- Net income TTM
- $-170,370,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -351.50%
- Debt to equity
- -0.38
Trading
- Volume
- 236,300
- Avg volume
- 407,888
- Day's range
- $10.19 – $11.19
- Shares out
- 6,111,000
- Stochastic %K
- 28%
- Beta
- 2.21
- Analysts
- Sell
- Price target
- $78.48
Company profile
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial f...
Show more
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 858 684 1300
- Website
- https://www.gossamerbio.com
- Address
- 3115 Merryfield Row, Suite 120, San Diego, United States
Latest news
No headlines yet.
